# Global Indemnity Group, LLC: financial statements, quarterly

GBLI · Nasdaq · CIK 1494904 · [Financials](/sectors/financials.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/gbli.md) · [Financials](/companies/gbli/financials.md) · [Filings](/companies/gbli/filings.md) · [Insiders](/companies/gbli/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/gbli/financials.md?period=annual).

## Income statement

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Revenue | $m | [126](/filings/0000950170-24-123335.md) | [109 d](/filings/0001193125-26-100467.md) | [112](/filings/0000950170-25-065766.md) | [109](/filings/0000950170-25-104150.md) | [112](/filings/0001193125-25-259858.md) | [108 d](/filings/0001193125-26-100467.md) | [109](/filings/0001193125-26-206792.md) | [111](/filings/0001193125-26-338196.md) | [114](/filings/0001193125-25-259858.md) | [117 d](/filings/0001193125-26-100467.md) | [109](/filings/0001193125-26-206792.md) | [116](/filings/0001193125-26-338196.md) |
| Interest expense | $m | [0.0](/filings/0000950170-24-123335.md) | [(0.0) d](/filings/0000950170-25-037300.md) | not reported | [0.0](/filings/0000950170-24-093715.md) | [0.0](/filings/0000950170-24-123335.md) | [(0.0) d](/filings/0000950170-25-037300.md) | not reported | not reported | not reported | not reported | not reported | not reported |
| Income tax | $m | [1.8](/filings/0000950170-24-123335.md) | [2.8 d](/filings/0001193125-26-100467.md) | [2.9](/filings/0000950170-25-065766.md) | [2.6](/filings/0000950170-25-104150.md) | [3.1](/filings/0001193125-25-259858.md) | [3.1 d](/filings/0001193125-26-100467.md) | [(1.1)](/filings/0001193125-26-206792.md) | [2.8](/filings/0001193125-26-338196.md) | [3.5](/filings/0001193125-25-259858.md) | [2.7 d](/filings/0001193125-26-100467.md) | [1.3](/filings/0001193125-26-206792.md) | [3.3](/filings/0001193125-26-338196.md) |
| Net income | $m | [7.7](/filings/0000950170-24-123335.md) | [5.9 d](/filings/0001193125-26-100467.md) | [11.4](/filings/0000950170-25-065766.md) | [10.1](/filings/0000950170-25-104150.md) | [12.8](/filings/0001193125-25-259858.md) | [9.0 d](/filings/0001193125-26-100467.md) | [(4.0)](/filings/0001193125-26-206792.md) | [10.3](/filings/0001193125-26-338196.md) | [12.5](/filings/0001193125-25-259858.md) | [6.5 d](/filings/0001193125-26-100467.md) | [4.2](/filings/0001193125-26-206792.md) | [11.1](/filings/0001193125-26-338196.md) |
| Diluted EPS | $ per share | [0.55](/filings/0000950170-24-123335.md) | not reported | [0.82](/filings/0000950170-25-065766.md) | [0.73](/filings/0000950170-25-104150.md) | [0.92](/filings/0001193125-25-259858.md) | not reported | [(0.30)](/filings/0001193125-26-206792.md) | [0.71](/filings/0001193125-26-338196.md) | [0.86](/filings/0001193125-25-259858.md) | not reported | [0.29](/filings/0001193125-26-206792.md) | [0.76](/filings/0001193125-26-338196.md) |
| Basic EPS | $ per share | [0.56](/filings/0000950170-24-123335.md) | not reported | [0.83](/filings/0000950170-25-065766.md) | [0.73](/filings/0000950170-25-104150.md) | [0.93](/filings/0001193125-25-259858.md) | not reported | [(0.30)](/filings/0001193125-26-206792.md) | [0.72](/filings/0001193125-26-338196.md) | [0.87](/filings/0001193125-25-259858.md) | not reported | [0.29](/filings/0001193125-26-206792.md) | [0.76](/filings/0001193125-26-338196.md) |

- Revenue: us-gaap:Revenues
- Interest expense: us-gaap:InterestExpense
- Income tax: us-gaap:IncomeTaxExpenseBenefit
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | Q3 FY2023 (2023-09-30) | FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | [46.5](/filings/0000950170-23-061610.md) | [38.0](/filings/0000950170-25-037300.md) | [38.9](/filings/0000950170-24-055565.md) | [46.7](/filings/0000950170-24-093715.md) | [31.0](/filings/0000950170-24-123335.md) | [17.0](/filings/0001193125-26-100467.md) | [81.1](/filings/0000950170-25-065766.md) | [67.3](/filings/0000950170-25-104150.md) | [75.4](/filings/0001193125-25-259858.md) | [65.5](/filings/0001193125-26-338196.md) | [34.8](/filings/0001193125-26-206792.md) | [97.5](/filings/0001193125-26-338196.md) |
| Total assets | $m | [1,768](/filings/0000950170-24-123335.md) | [1,730](/filings/0001193125-26-100467.md) | [1,728](/filings/0000950170-25-065766.md) | [1,739](/filings/0000950170-25-104150.md) | [1,761](/filings/0001193125-25-259858.md) | [1,731](/filings/0001193125-26-100467.md) | [1,714](/filings/0001193125-26-206792.md) | [1,721](/filings/0001193125-26-338196.md) | [1,734](/filings/0001193125-25-259858.md) | [1,721](/filings/0001193125-26-338196.md) | [1,680](/filings/0001193125-26-206792.md) | [1,723](/filings/0001193125-26-338196.md) |
| Total liabilities | $m | [1,137](/filings/0000950170-23-061610.md) | [1,081](/filings/0000950170-25-037300.md) | [1,069](/filings/0000950170-24-055565.md) | [1,071](/filings/0000950170-24-093715.md) | [1,074](/filings/0000950170-24-123335.md) | [1,042](/filings/0001193125-26-100467.md) | [1,027](/filings/0000950170-25-065766.md) | [1,025](/filings/0000950170-25-104150.md) | [1,030](/filings/0001193125-25-259858.md) | [1,014](/filings/0001193125-26-338196.md) | [976](/filings/0001193125-26-206792.md) | [1,013](/filings/0001193125-26-338196.md) |
| Long-term debt | $m | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported | not reported |
| Shareholders' equity | $m | [631](/filings/0000950170-24-123335.md) | [649](/filings/0001193125-26-100467.md) | [659](/filings/0000950170-25-065766.md) | [667](/filings/0000950170-25-104150.md) | [687](/filings/0001193125-25-259858.md) | [689](/filings/0001193125-26-100467.md) | [687](/filings/0001193125-26-206792.md) | [695](/filings/0001193125-26-338196.md) | [704](/filings/0001193125-25-259858.md) | [707](/filings/0001193125-26-338196.md) | [704](/filings/0001193125-26-206792.md) | [711](/filings/0001193125-26-338196.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Total assets: us-gaap:Assets
- Total liabilities: us-gaap:Liabilities
- Long-term debt: not reported
- Shareholders' equity: us-gaap:StockholdersEquity

## Cash flow

| Line item | Unit | Q3 FY2023 (2023-09-30) | Q4 FY2023 (2023-12-31) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q4 FY2024 (2024-12-31) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q4 FY2025 (2025-12-31) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Operating cash flow | $m | [22.6 d](/filings/0000950170-24-123335.md) | [6.1 d](/filings/0001193125-26-100467.md) | [22.7](/filings/0000950170-25-065766.md) | [14.3 d](/filings/0000950170-25-104150.md) | [15.3 d](/filings/0001193125-25-259858.md) | [(13.4) d](/filings/0001193125-26-100467.md) | [2.4](/filings/0001193125-26-206792.md) | [7.0 d](/filings/0001193125-26-338196.md) | [5.7 d](/filings/0001193125-25-259858.md) | [(6.0) d](/filings/0001193125-26-100467.md) | [(17.9)](/filings/0001193125-26-206792.md) | [(15.8) d](/filings/0001193125-26-338196.md) |
| Dividends paid | $m | [0.0 d](/filings/0000950170-24-123335.md) | [6.8 d](/filings/0001193125-26-100467.md) | [4.8](/filings/0000950170-25-065766.md) | [5.0 d](/filings/0000950170-25-104150.md) | [0.0 d](/filings/0001193125-25-259858.md) | [9.6 d](/filings/0001193125-26-100467.md) | [5.0](/filings/0001193125-26-206792.md) | [5.0 d](/filings/0001193125-26-338196.md) | [0.0 d](/filings/0001193125-25-259858.md) | [10.0 d](/filings/0001193125-26-100467.md) | [5.0](/filings/0001193125-26-206792.md) | [5.0 d](/filings/0001193125-26-338196.md) |
| Share repurchases | $m | [0.0 d](/filings/0000950170-24-123335.md) | [0.0 d](/filings/0001193125-26-100467.md) | [0.0](/filings/0000950170-24-055565.md) | [0.5 d](/filings/0000950170-25-104150.md) | [0.0 d](/filings/0001193125-25-259858.md) | [0.0 d](/filings/0001193125-26-100467.md) | not reported | not reported | not reported | [0.0 d](/filings/0001193125-26-100467.md) | not reported | not reported |

- Operating cash flow: us-gaap:NetCashProvidedByUsedInOperatingActivities
- Dividends paid: us-gaap:PaymentsOfDividendsCommonStock
- Share repurchases: us-gaap:PaymentsForRepurchaseOfCommonStock

## Shares

| Line item | Unit | Q3 FY2022 (2022-09-30) | Q1 FY2023 (2023-03-31) | Q2 FY2023 (2023-06-30) | Q3 FY2023 (2023-09-30) | Q1 FY2024 (2024-03-31) | Q2 FY2024 (2024-06-30) | Q3 FY2024 (2024-09-30) | Q1 FY2025 (2025-03-31) | Q2 FY2025 (2025-06-30) | Q3 FY2025 (2025-09-30) | Q1 FY2026 (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [14.8](/filings/0000950170-23-061610.md) | [13.9](/filings/0000950170-24-055565.md) | [13.7](/filings/0000950170-24-093715.md) | [13.8](/filings/0000950170-24-123335.md) | [13.7](/filings/0000950170-25-065766.md) | [13.7](/filings/0000950170-25-104150.md) | [13.8](/filings/0001193125-25-259858.md) | [13.9](/filings/0001193125-26-206792.md) | [14.3](/filings/0001193125-26-338196.md) | [14.4](/filings/0001193125-25-259858.md) | [14.4](/filings/0001193125-26-206792.md) | [14.4](/filings/0001193125-26-338196.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:41 ET. No prices; not investment advice.